US20230042445A1 - Use of mitochondria to promote wound repair and/or wound healing - Google Patents

Use of mitochondria to promote wound repair and/or wound healing Download PDF

Info

Publication number
US20230042445A1
US20230042445A1 US17/912,336 US202117912336A US2023042445A1 US 20230042445 A1 US20230042445 A1 US 20230042445A1 US 202117912336 A US202117912336 A US 202117912336A US 2023042445 A1 US2023042445 A1 US 2023042445A1
Authority
US
United States
Prior art keywords
mitochondria
wound
cells
prf
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US17/912,336
Other languages
English (en)
Inventor
Han-Chung CHENG
Chih-Kai Hsu
Hui-Ching TSENG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiwan Mitochondrion Application Technology Co Ltd
Original Assignee
Taiwan Mitochondrion Application Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiwan Mitochondrion Application Technology Co Ltd filed Critical Taiwan Mitochondrion Application Technology Co Ltd
Priority to US17/912,336 priority Critical patent/US20230042445A1/en
Assigned to TAIWAN MITOCHONDRION APPLIED TECHNOLOGY CO., LTD. reassignment TAIWAN MITOCHONDRION APPLIED TECHNOLOGY CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHENG, HAN-CHUNG, HSU, CHIH-KAI, TSENG, Hui-Ching
Publication of US20230042445A1 publication Critical patent/US20230042445A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/02—Blood transfusion apparatus
    • A61M1/029—Separating blood components present in distinct layers in a container, not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3693—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C12N2500/84—Undefined extracts from animals from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/115—Platelets, megakaryocytes

Definitions

  • the present invention relates to a second use of mitochondria, and in particular to a use of mitochondria to promote wound repair and/or wound healing.
  • Wound healing is a continuous and complicated biological response process, which can be roughly divided into several stages, including hemostatic, inflammatory, proliferative, and tissue remodeling phases.
  • the length of the healing time is affected by external or internal factors. That is, when the wounded person has poor blood circulation, is old, is a diabetic, or has a bacterial infection, the time required for wound recovery is likely to increase.
  • the present invention mainly aims to provide a use of mitochondria to promote wound repair and/or wound healing. Specifically, because of the mitochondria's ability to promote cell migration of fibroblasts and increase the expression level of collagen, by administering an effective amount of mitochondria or a composition containing the effective amount of mitochondria to a wound, the effect of promoting wound repair or healing can be effectively achieved, thus reducing or alleviating wound deterioration or persistent inflammation.
  • Another objective of the present invention is to provide a composition containing mitochondria and other substances containing growth factors, which can significantly improve cell repair and tissue regeneration, or alleviate cellular inflammation, so as to reduce the chance of inflammation-related complications.
  • the present invention discloses a composition which includes mitochondria and a blood product, where the blood product contains at least one growth factor, such as platelet-rich plasma (PRP), plasma, serum, or platelet-rich fibrin (PRF).
  • the blood product contains at least one growth factor, such as platelet-rich plasma (PRP), plasma, serum, or platelet-rich fibrin (PRF).
  • PRP platelet-rich plasma
  • PRF platelet-rich fibrin
  • the present invention discloses a use of mitochondria for preparing a composition for repairing wounds or promoting wound healing, where the composition is administered to an affected part, thus improving the healing efficiency of the affected part.
  • a use of mitochondria for preparing a composition for promoting tissue regeneration is provided. Therefore, by administering an effective amount of mitochondria to a wound, inflammation of the wound can be inhibited or alleviated, thus avoiding inflammation-related complications.
  • the effective amount of the mitochondria in the composition at least ranges from 5 ⁇ g to 80 ⁇ g, and is preferably above 40 ⁇ g.
  • the mitochondria are separated out from cells, such as adipose-derived stem cells or mesenchymal stem cells, and the cells may be autologous or heterologous.
  • the composition further includes platelet-rich fibrin, and the effective amount of the mitochondria in the composition is at least 15 ⁇ g.
  • compositions which includes mitochondria and platelet-rich fibrin (PRF).
  • the dose of the mitochondria ranges from 5 ⁇ g to 80 ⁇ g, and preferably ranges from 15 ⁇ g to 40 ⁇ g; and the concentration of the PRF is preferably above 5 volume percent (v/v %).
  • the wound healing can be promoted, so as to achieve the effect of accelerating wound repair and avoiding wound inflammation or related complications.
  • FIG. 1 A shows a result of observing CCD-966SK cells subjected to treatments with different doses of mitochondria and a cell migration assay
  • FIG. 1 B shows cell migration ratios of the CCD-966SK cells subjected to different treatments in FIG. 1 A after statistical analysis
  • FIG. 2 shows a statistical analysis result regarding a collagen secretion amount after the CCD-966SK cells are treated with different doses of mitochondria
  • FIG. 3 A shows a result of observing CCD-966SK cells subjected to PRF treatments with different doses of mitochondria and a cell migration assay
  • FIG. 3 B shows cell migration ratios of the CCD-966SK cells subjected to different treatments in FIG. 3 A after statistical analysis
  • FIG. 4 is a statistical analysis result regarding a collagen secretion amount after the CCD-966SK cells are subjected to PRF treatments with different doses of mitochondria;
  • FIG. 5 shows results of observing wound recovery after PRF containing different doses of mitochondria is applied to the wound in a mouse
  • FIG. 6 shows a result of cell growth efficiency calculated after the CCD-966SK cells are cultured in cell culture media added with different doses of mitochondria.
  • the present invention provides a use of mitochondria to promote wound repair and/or wound healing.
  • the effective amount for administration of the mitochondria disclosed in the present invention ranges from 1 ⁇ g to 80 ⁇ g, such as 1 ⁇ g, 2 ⁇ g, 4 ⁇ g, 5 ⁇ g, 10 ⁇ g, 15 ⁇ g, 20 ⁇ g, 25 ⁇ g, 30 ⁇ g, 40 ⁇ g, 50 ⁇ g, 60 ⁇ g, 65 ⁇ g, 70 ⁇ g or 80 ⁇ g
  • the effective amount of the mitochondria preferably ranges from 15 ⁇ g to 40 ⁇ g, thus achieving a better treatment effect or improving wound repair or promoting wound healing.
  • the mitochondria disclosed in the present invention can be mixed with another component to prepare a composition, where the used component is preferably a material containing a growth factor and more preferably a blood product containing growth factors.
  • the blood product containing growth factors is platelet-rich fibrin (hereafter as PRF) which contains a variety of growth factors, such as PDGF-AA (15.6 to 1000 pg/ml), PDGF-AB (15.6 to 1000 pg/ml), PDGF-BB (31.2 to 2000 pg/ml), TGF- ⁇ 1 (31.2 to 2000 pg/ml), VEGF (31.2 to 2000 pg/ml), EGF (31.2 to 2000 pg/ml), IGF (31.2 to 2000 pg/ml), etc.
  • PRF platelet-rich fibrin
  • mitochondria refers to mitochondria that have functional and structural integrity and are separated out from non-autologous or autologous cells.
  • the types of the cells are not limited, including, but not limited to, adipose-derived stem cells, mesenchymal stem cells, skeletal muscle cells, liver cells, kidney cells, fibroblasts, nerve cells, skin cells, blood cells, and the like.
  • composition refers to which includes at least containing an effective amount of mitochondria, such as a pharmaceutical product, a pharmaceutical beauty product, etc.
  • the composition is prepared in different dosage forms, such as drops, emulsion, paste, etc., according to the mode of use or administration, and is formed by mixing different components, such as growth factors, PRF, or a blood product containing the foregoing substances.
  • the “blood product” mentioned in the present invention refers to a product prepared by using the blood as the raw material, and contains a certain amount of growth factors, such as PRF separated out from the whole blood, blood added with growth factors, platelet-rich plasma (hereafter as PRP), plasma, serum, or the like.
  • growth factors such as PRF separated out from the whole blood, blood added with growth factors, platelet-rich plasma (hereafter as PRP), plasma, serum, or the like.
  • PRP platelet-rich plasma
  • serum serum
  • the “administration” mentioned in the present invention refers to enabling the mitochondria disclosed in the present invention to contact the injured part, and the way of contacting the injured part is not limited to smearing, dripping, injecting, introducing, etc.
  • an external force such as ultrasound waves, shockwaves, heating, or the like, is further utilized to strengthen or accelerate the uptake by the cells.
  • CCD-966SK human skin fibroblasts
  • HU Hydroxyurea
  • the culture of CCD-966SK cells was performed by using a Dulbecco's Modified Eagle's Medium (DMEM) added with 10% fetal calf serum and/or 2 mM L-glutamine in a 37° C. incubator having 5% carbon dioxide.
  • DMEM Dulbecco's Modified Eagle's Medium
  • the cell culture medium was removed and the phosphate buffer solution was used for rinsing.
  • the phosphate buffer solution was removed and 0.25% trypsin was added in to react at 37° C. for 5 min.
  • the cell culture medium was added in to neutralize the trypsin, and centrifugation was performed at 1000 rpmfor 5 min. The supernatant was removed after centrifugation; and a new cell culture fluid was added in and cell counting was performed.
  • Cell subculture was performed according to the needs of subsequent examples.
  • the PRF contains a variety of growth factors. Among these contained and verified various growth factors, PDGF-AA (15.6-1000 pg/ml), PDGF-AB (15.6-1000 pg/ml), PDGF-BB (31.2-2000 pg/ml), TGF- ⁇ 1 (31.2-2000 pg/ml), VEGF (31.2-2000 pg/ml), EGF (31.2-2000 pg/ml), and IGF (31.2-2000 pg/ml) are common.
  • the prepared PRF was added to the cell culture medium at 5 percent by volume or to an animal solvent to be injected, to prepare a PRF solution with a volume percentage concentration of 5%.
  • the human adipose-derived stem cells were cultured to obtain 1.5 ⁇ 10 8 cells, and the Duchenne phosphate buffer solution (DPBS) was used to flush the cells and then was removed. Trypsin was added in to react for 3 min, and then a stem cell culture liquid (Keratinocyte SFM (1X) liquid, bovine pituitary extract, or 10 wt% fetal calf serum) was added in to terminate the reaction. Afterwards, the cells were collected and centrifuged (600 g for 10 min), and the supernatant was removed.
  • DPBS Duchenne phosphate buffer solution
  • the buffer solution is compounded of 225 mM mannitol, 75 mM sucrose, 0.1 mM EDTA, and 30 mM Tris-HCl with pH of 7.4
  • 80 ml IBC-1 buffer solution was added to the cells, and centrifugation was conducted after homogenization, to obtain a precipitate that was the mitochondria (referred to as a mitochondrial precipitate in the following description).
  • 1.5 ml IBC-1 buffer solution and a proteolytic enzyme inhibitor were added to the mitochondrial precipitate, and then the mitochondrial precipitate was placed aside in a 4° C. environment, for use in the following examples.
  • the CCD-966SK cells cultured in Example 1 were cultured in a 24-well plate at a concentration of 2 ⁇ 10 4 cells/0.25 ml per well, for 24 hours. After it was confirmed that the cell completeness reached 90%, the phosphate buffer solution was used to clean the cells and a cell culture medium without the addition of 10% fetal calf serum was used to replace the original medium to continuously culture the cells for 8 hours. Afterwards, a straight wound of a fixed width was scraped in the middle of the cell. The cell culture liquid and the cells in suspension were removed, a cell culture liquid containing 10 ⁇ M HU was used to replace the original liquid, and mitochondria with different concentrations (15 ⁇ g and 40 ⁇ g) were separately added in to perform culturing for 24 hours. After 24-hour culturing, cell migration was performed, to obtain results shown in FIGS. 1 A and 1 B through observation and analysis.
  • the administration of the mitochondria can effectively promote the movement of the fibroblasts towards the injured part, and as the administration dose of the mitochondria increases, the fibroblasts move faster.
  • FIG. 1 B by using a blank group not subjected to a treatment with any mitochondria as a reference (100%) for calculation of the cell migration proportion, the cell migration proportion of the CCD-966SK cells subjected to a treatment with 15 ⁇ g mitochondria is 149.4 ⁇ 40.9% and the cell migration proportion of those subjected to a treatment with 40 ⁇ g mitochondria is 160.4 ⁇ 26.1% through calculation.
  • the results of this example show that the mitochondria can indeed promote the movement of the fibroblasts towards the wound, thereby accelerating wound healing or promoting wound repair.
  • the process of this example was substantially identical with that in Example 4, but had the following differences.
  • the cell supernatant was collected and a collagen secretion assay was performed by using the SircolTM Soluble Collagen Assay Kit, to obtain a result shown in FIG. 2 .
  • a collagen expression amount of the blank group is 5.85 ⁇ 0.1 ⁇ g/ml; a collagen expression amount of the CCD-966SK cells subjected to a treatment with 15 ⁇ g mitochondria is 15.1 ⁇ 0.3 ⁇ g/ml; and a collagen expression amount of the CCD-966SK cells subjected to a treatment with 40 ⁇ g mitochondria is 25.3 ⁇ 0.3 ⁇ g/ml.
  • the result indicates that in the case of simulation of cell damage, the CCD-966SK cells subjected to a treatment with mitochondria can secrete more collagen; and moreover, the expression level of the collagen rises as the administration dose of the mitochondria increases.
  • the mitochondria can indeed improve a collagen expression amount of the fibroblasts, thereby accelerating wound healing or promoting wound repair.
  • Example 4 The process of this example was substantially identical with that in Example 4, but had the following differences.
  • a cell culture liquid containing 10 ⁇ M HU was used; and the PRF (prepared in Example 2), 15 ⁇ g mitochondria and 5 vol% PRF, and 40 ⁇ g mitochondria and 5 vol% PRF were separately added in to perform culturing for 24 hours. After culture completion, cell migration was observed and analyzed, to obtain results shown in FIGS. 3 A and 3 B .
  • a cell migration proportion of the CCD-966SK cells in the blank group is 100%; a cell migration proportion of the CCD-966SK cells subjected to a treatment with the PRF is 156.8 ⁇ 16.0%; a cell migration proportion of the CCD-966SK cells subjected to a treatment with the PRF and 15 ⁇ g mitochondria is 185.4 ⁇ 40.9%; and a cell migration proportion of the CCD-966SK cells subjected to a treatment with the PRF and 40 ⁇ g mitochondria is 202.0 ⁇ 30.9%.
  • the foregoing result shows that, although the administration of only the PRF can promote the migration of the fibroblasts, the administration of both the PRF and the mitochondria can obviously improve the migration proportion of the fibroblasts. Moreover, as the dose of the mitochondria increases, a better cell migration effect can be achieved. That is, by administering a certain amount of mitochondria disclosed in the present invention to the wound or injured tissue, the effect of promoting wound recovery can be achieved.
  • Example 5 The process of this example was substantially identical with that in Example 5, but had the following differences.
  • the cell supernatant was collected and a collagen secretion assay was performed by using a soluble collagen assay kit, to obtain a result shown in FIG. 4 .
  • a collagen expression amount of the blank group is 5.85 ⁇ 0.1 ⁇ g/ml; a collagen expression amount of the CCD-966SK cells subjected to a treatment with the PRF is 342.51 ⁇ 15.84 ⁇ g/ml; a collagen expression amount of the CCD-966SK cells subjected to a treatment with the PRF and 15 ⁇ g mitochondria is 1107.33 ⁇ 87.97 ⁇ g/ml; and a collagen expression amount of the CCD-966SK cells subjected to a treatment with the PRF and 40 ⁇ g mitochondria is 1413.4 ⁇ 158.72 ⁇ g/ml.
  • FIG. 4 shows that a collagen expression amount of the CCD-966SK cells subjected to the treatment with both the PRF and the mitochondria is obviously higher than that of the secretion from the CCD-966SK cells subjected to the treatment with only the PRF; and moreover, a collagen expression amount rises as the administration dose of the mitochondria increases.
  • the administering the mitochondria disclosed in the present invention to the wound or the injured tissue can indeed promote wound recovery, and its ability to promote wound recovery is obviously higher than the PRF.
  • the CCD-966SK cells were used and cultured under the same conditions for 4 hours. Then, different doses (0 ⁇ g, 1 ⁇ g, 15 ⁇ g, and 40 ⁇ g) of mitochondria were administered in the cell culture process as a supplement to the cell culture medium to perform cell culturing for 24 hours. Afterwards, a culture medium containing alamar blue was used to continue culturing for 3 hours, and then a cell growth efficiency of each group was estimated by means of a wavelength of OD 530/595 nm, to obtain a result shown in FIG. 6 .
  • the cell culture medium of each group is shown in the following table 1.
  • Table 1 Composition of the cell culture medium in each group Groups Control group (0 ⁇ g mitochondria) Group of using 1 ⁇ g mitochondria Group of using 15 ⁇ g mitochondria Group of using 40 ⁇ g mitochondria
  • Control group (0 ⁇ g mitochondria) Group of using 1 ⁇ g mitochondria Group of using 15 ⁇ g mitochondria Group of using 40 ⁇ g mitochondria
  • Cell culture media DEME/2 mM L-glutamine; 10%fetal calf serum DEME/2 mM L-glutamine; 10%fetal calf serum; 1 ⁇ g mitochondria DEME/2 mM L-glutamine; 10%fetal calf serum; 15 ⁇ g mitochondria DEME/2 mM L-glutamine; 10%fetal calf serum; 40 ⁇ g mitochondria
  • the cell growth efficiency of the group not added with the mitochondria achieves a ratio of 1.16 ⁇ 0.08, the cell growth efficiency of the group added with 1 ⁇ g mitochondria achieves a ratio of 1.17 ⁇ 0.06, the cell growth efficiency of the group added with 15 ⁇ g mitochondria achieves a ratio of 1.28 ⁇ 0.08, and the cell growth efficiency of the group added with 40 ⁇ g mitochondria achieves a ratio of 1.31 ⁇ 0.07.
  • the cell growth efficiency of the group not added with the mitochondria achieves a ratio of 1.77 ⁇ 0.06
  • the cell growth efficiency of the group added with 1 ⁇ g mitochondria achieves a ratio of 1.77 ⁇ 0.07
  • the cell growth efficiency of the group added with 15 ⁇ g mitochondria achieves a ratio of 1.90 ⁇ 0.12
  • the cell growth efficiency of the group added with 40 ⁇ g mitochondria achieves a ratio of 2.20 ⁇ 0.16.
  • the result of FIG. 6 shows that the addition of the mitochondria in the culture process of the CCD-966SK cells can improve the cell growth efficiency, and the growth efficiency rises as the concentration of the mitochondria increases, thus achieving the effect of promoting cell proliferation, tissue regeneration and repair.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
US17/912,336 2020-03-20 2021-03-19 Use of mitochondria to promote wound repair and/or wound healing Pending US20230042445A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/912,336 US20230042445A1 (en) 2020-03-20 2021-03-19 Use of mitochondria to promote wound repair and/or wound healing

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062992546P 2020-03-20 2020-03-20
US17/912,336 US20230042445A1 (en) 2020-03-20 2021-03-19 Use of mitochondria to promote wound repair and/or wound healing
PCT/CN2021/081685 WO2021185340A1 (zh) 2020-03-20 2021-03-19 线粒体用于促进伤口修复及/或伤口愈合的用途

Publications (1)

Publication Number Publication Date
US20230042445A1 true US20230042445A1 (en) 2023-02-09

Family

ID=77768010

Family Applications (6)

Application Number Title Priority Date Filing Date
US17/912,336 Pending US20230042445A1 (en) 2020-03-20 2021-03-19 Use of mitochondria to promote wound repair and/or wound healing
US17/912,394 Pending US20230137870A1 (en) 2020-03-20 2021-03-19 Use of mitochondrial extract to treat and/or prevent kidney injury-related disease
US17/912,458 Pending US20230165899A1 (en) 2020-03-20 2021-03-19 Use of mitochondria to treat and/or prevent tendon injury or its related disease
US17/947,994 Pending US20230023218A1 (en) 2020-03-20 2022-09-19 Use of a cell culture composition for promoting cell growth
US17/948,007 Pending US20230023438A1 (en) 2020-03-20 2022-09-19 Composition comprising mitochondria and use thereof for repairing cartilage damage or improving osteoarthritis
US17/948,764 Pending US20230016499A1 (en) 2020-03-20 2022-09-20 Method for manufacturing mitochondria-rich plasma

Family Applications After (5)

Application Number Title Priority Date Filing Date
US17/912,394 Pending US20230137870A1 (en) 2020-03-20 2021-03-19 Use of mitochondrial extract to treat and/or prevent kidney injury-related disease
US17/912,458 Pending US20230165899A1 (en) 2020-03-20 2021-03-19 Use of mitochondria to treat and/or prevent tendon injury or its related disease
US17/947,994 Pending US20230023218A1 (en) 2020-03-20 2022-09-19 Use of a cell culture composition for promoting cell growth
US17/948,007 Pending US20230023438A1 (en) 2020-03-20 2022-09-19 Composition comprising mitochondria and use thereof for repairing cartilage damage or improving osteoarthritis
US17/948,764 Pending US20230016499A1 (en) 2020-03-20 2022-09-20 Method for manufacturing mitochondria-rich plasma

Country Status (6)

Country Link
US (6) US20230042445A1 (https=)
EP (2) EP4122474A4 (https=)
JP (2) JP7563782B2 (https=)
CN (16) CN118557602A (https=)
TW (12) TWI789724B (https=)
WO (6) WO2021185364A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI789724B (zh) * 2020-03-20 2023-01-11 台灣粒線體應用技術股份有限公司 粒線體用於治療及/或預防肌腱受損或其相關疾病之用途
US20250186498A1 (en) * 2022-05-16 2025-06-12 Taiwan Mitochondrion Applied Technology Co., Ltd. Composition for hearing loss mitigation and use thereof
CN116478920B (zh) * 2023-05-05 2025-03-25 重庆理工大学 一种离体线粒体的体外储存方法
CN117180312A (zh) * 2023-10-09 2023-12-08 上海市第六人民医院 iMSCs线粒体在制备治疗骨缺损的药物中的应用
CN117883479A (zh) * 2023-11-02 2024-04-16 上海市第六人民医院 人源线粒体在制备治疗跟腱损伤的药物中的应用
WO2025126112A1 (en) * 2023-12-12 2025-06-19 Cells For Cells S.A. Composition enriched in mitochondria isolated from umbilical cord mesenchymal stem cells, useful in osteoarthritis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180057610A1 (en) * 2016-01-15 2018-03-01 Children's Medical Center Corporation Therapeutic Use of Mitochondria and Combined Mitochondrial Agent

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0202298B1 (en) * 1984-11-29 1992-07-15 Regents Of The University Of Minnesota Wound healing agents
US6100068A (en) * 1997-01-21 2000-08-08 Paik-Inje Memorial Institute For Biomedical Science Method of protein production using mitochondrial translation system
US5834418A (en) * 1996-03-20 1998-11-10 Theratechnologies, Inc. Process for the preparation of platelet growth factors extract
US7005274B1 (en) * 1999-09-15 2006-02-28 Migenix Corp. Methods and compositions for diagnosing and treating arthritic disorders and regulating bone mass
BRPI0507349A (pt) * 2004-02-02 2007-04-17 Nestec Sa genes associados á osteoartrite canina e processos e composições relacionados
TW200817019A (en) * 2006-07-10 2008-04-16 Univ Columbia De novo formation and regeneration of vascularized tissue from tissue progenitor cells and vascular progenitor cells
WO2009002811A2 (en) * 2007-06-22 2008-12-31 Children's Medical Center Corporation Therapeutic platelet compositions and methods
US8734854B2 (en) * 2009-07-09 2014-05-27 Orogen Biosciences Inc. Process for removing growth factors from platelets
US20130022666A1 (en) * 2011-07-20 2013-01-24 Anna Brzezinska Methods and compositions for transfer of mitochondria into mammalian cells
EP2741757B1 (en) * 2011-09-11 2018-05-16 Minovia Therapeutics Ltd. Compositions of functional mitochondria and uses thereof
EP2591812A1 (en) * 2011-11-14 2013-05-15 University of Twente, Institute for Biomedical Technology and Technical Medicine (MIRA) A dextran-based tissuelette containing platelet-rich plasma lysate for cartilage repair
US20140024677A1 (en) * 2012-04-09 2014-01-23 Musc Foundation For Research Development Methods for inducing mitochondrial biogenesis
US10702556B2 (en) * 2012-05-16 2020-07-07 Minovia Therpautices Ltd. Compositions and methods for inducing angiogenesis
AU2013326861A1 (en) * 2012-10-04 2015-04-23 Genesys Research Institute Platelet compositions and uses thereof
CN105163750B (zh) * 2013-02-07 2022-07-15 李震义 长效人重组可溶性肿瘤坏死因子α受体在制备预防和治疗慢性肝病重症肝损伤药物中的用途
US20140271589A1 (en) * 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
ES2883580T3 (es) * 2013-03-21 2021-12-09 Collplant Ltd Composiciones que comprenden colágeno y PRP para la regeneración de tejidos y su método de producción
US20150064715A1 (en) * 2013-08-28 2015-03-05 Musc Foundation For Research Development Urinary biomarkers of renal and mitochondrial dysfunction
TW201509425A (zh) * 2013-09-13 2015-03-16 Taichung Hospital Ministry Of Health And Welfare 以血液製備修復傷口用醫藥組合物之方法
TWI672147B (zh) * 2014-09-10 2019-09-21 台灣粒線體應用技術股份有限公司 以外源性粒線體爲有效成份之組合物、其用途及修復細胞之方法
JP6441472B2 (ja) * 2014-09-30 2018-12-19 台灣粒線體應用技術股▲扮▼有限公司Ｔａｉｗａｎ Ｍｉｔｏｃｈｏｎｄｒｉｏｎ Ａｐｐｌｉｅｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．，Ｌｔｄ． 活性成分として外因性ミトコンドリアを含む組成物、ならびにその使用およびそのための細胞修復法
CN105520891B (zh) * 2014-09-30 2019-05-21 台湾粒线体应用技术股份有限公司 以外源性线粒体为有效成份的组合物、其用途及修复细胞的方法
CN107249600A (zh) * 2014-12-31 2017-10-13 台湾粒线体应用技术股份有限公司 新颖医药组合物及其用于治疗肺损伤的用途
WO2016114781A1 (en) * 2015-01-15 2016-07-21 Boss William K Jr Repair and rejuvenation of tissues using platelet-rich plasma
CN104546915B (zh) * 2015-02-16 2018-12-11 天晴干细胞股份有限公司 一种治疗骨性关节炎的组合物的制备方法
IL299482B2 (en) * 2015-02-26 2025-02-01 Minovia Therapeutics Ltd Mammalian cells are enriched with active mitochondria
CA2987271A1 (en) * 2015-05-22 2016-12-01 President And Fellows Of Harvard College Methods, systems, and compositions for determining blood clot formation, and uses thereof
CN105030647B (zh) * 2015-09-14 2018-04-24 广州赛莱拉干细胞科技股份有限公司 一种减少皱纹的制剂及其制备方法
US20180303970A1 (en) * 2015-11-02 2018-10-25 VeriGraft AB Compositions and methods for healing wounds
US11903974B2 (en) * 2015-11-30 2024-02-20 Flagship Pioneering Innovations V, Inc. Methods and compositions relating to chondrisomes from cultured cells
CN105477018A (zh) * 2015-12-07 2016-04-13 深圳爱生再生医学科技有限公司 修复皮肤溃疡的干细胞制剂及其制备方法
US20170224764A1 (en) * 2016-02-10 2017-08-10 Cornell University Therapeutic targeting of mitochondria to prevent osteoarthritis
TWI637748B (zh) * 2016-07-12 2018-10-11 中山醫學大學 蓮蓬萃取物用於治療及／或預防腎臟病變之用途
CN106190963A (zh) * 2016-07-13 2016-12-07 浙江大学 一种采用线粒体移植促进损伤神经元存活的方法
EP3549589A4 (en) * 2016-11-30 2020-07-15 Paean Biotechnology Inc. PHARMACEUTICAL COMPOSITION CONTAINING MITOCHONDRIA
CN106822183B (zh) * 2016-12-26 2020-04-14 中山光禾医疗科技有限公司 一种光敏富血小板血浆凝胶及其制备方法和用途
US20200023005A1 (en) * 2017-03-26 2020-01-23 Minovia Therapeutics Ltd. Mitochondrial compositions and methods for treatment of skin and hair
US20200268940A1 (en) * 2017-05-15 2020-08-27 Richard J. Miron Liquid platelet-rich fibrin as a carrier system for biomaterials and biomolecules
EP3630134B8 (en) * 2017-06-01 2022-01-19 The United States of America as represented by The Secretary Department of Health and Human Services Formation of stable cartilage
US20190008896A1 (en) * 2017-07-07 2019-01-10 Richard Postrel Methods and Systems for the Prevention, Treatment and Management of Disease and Effects of Aging Via Cell-to-Cell Restoration Therapy Using Subcellular Transactions
CN107625969A (zh) * 2017-10-18 2018-01-26 南京市儿童医院 MiR‑214拮抗剂在制备用于减轻蛋白尿引起的肾小管损伤相关病症的药物中的用途
WO2019083201A2 (ko) * 2017-10-24 2019-05-02 주식회사 엑소코바이오 지방줄기세포 유래의 엑소좀을 유효성분으로 포함하는 조성물의 신장 기능 개선 용도
KR20190052266A (ko) * 2017-11-08 2019-05-16 원광대학교산학협력단 우르솔산을 유효성분으로 포함하는 신장 기능의 개선 또는 치료용 조성물
KR102275822B1 (ko) * 2018-02-02 2021-07-12 주식회사 파이안바이오테크놀로지 분리된 미토콘드리아를 포함하는 류마티스 관절염 예방 또는 치료용 약학 조성물
CN112154210A (zh) * 2018-03-13 2020-12-29 利兰斯坦福初级大学董事会 用于逆转细胞老化的瞬时细胞重编程
WO2019183042A1 (en) * 2018-03-20 2019-09-26 Unity Biotechnology, Inc. Autologous mitochondrial extraction and expansion
US12329781B2 (en) * 2018-07-22 2025-06-17 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of renal diseases
CN112601532A (zh) * 2018-07-22 2021-04-02 米诺维亚疗法有限公司 使用富集有功能性线粒体的干细胞的线粒体增强疗法
US12268714B2 (en) * 2018-09-14 2025-04-08 Luca Science Inc. Transplantation of mitochondria into lymphoid organ and composition therefor
KR102128003B1 (ko) * 2018-10-31 2020-06-29 차의과학대학교 산학협력단 분리된 미토콘드리아를 포함하는 건병증 예방 또는 치료용 약학 조성물
CN110055216A (zh) * 2019-05-09 2019-07-26 张秀明 一种改善间质干细胞生物学功能的方法
CN110638833A (zh) * 2019-11-15 2020-01-03 西安圣德生物科技有限公司 促进毛发生长的组合物及其使用方法
CN110812480B (zh) * 2019-11-28 2021-04-02 中国科学院昆明动物研究所 一种抗菌肽和线粒体dna复合物及其多克隆抗体和应用
TWI789724B (zh) * 2020-03-20 2023-01-11 台灣粒線體應用技術股份有限公司 粒線體用於治療及/或預防肌腱受損或其相關疾病之用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180057610A1 (en) * 2016-01-15 2018-03-01 Children's Medical Center Corporation Therapeutic Use of Mitochondria and Combined Mitochondrial Agent

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Ding et al. Platelet-Rich Fibrin Accelerates Skin Wound Healing in Diabetic Mice. Ann Plast Surg 2017;79: e15–e19 (Year: 2017) *
Samson et al. Mitochondrial changes in developing rat brain. Am. J. Physiol. 199(4); p.693-696 (Year: 1960) *

Also Published As

Publication number Publication date
CN118252850A (zh) 2024-06-28
US20230023438A1 (en) 2023-01-26
US20230137870A1 (en) 2023-05-04
CN115103683A (zh) 2022-09-23
TW202308668A (zh) 2023-03-01
TWI789723B (zh) 2023-01-11
WO2021185340A1 (zh) 2021-09-23
WO2021185364A1 (zh) 2021-09-23
EP4122474A1 (en) 2023-01-25
CN117379458A (zh) 2024-01-12
JP2023518083A (ja) 2023-04-27
US20230023218A1 (en) 2023-01-26
CN115297872B (zh) 2024-03-29
CN115315248A (zh) 2022-11-08
JP7563782B2 (ja) 2024-10-08
TWI849298B (zh) 2024-07-21
TW202135779A (zh) 2021-10-01
CN115335065A (zh) 2022-11-11
WO2021185376A1 (zh) 2021-09-23
CN115315265A (zh) 2022-11-08
CN115315265B (zh) 2024-05-31
TW202504624A (zh) 2025-02-01
CN118319950A (zh) 2024-07-12
TW202135837A (zh) 2021-10-01
CN115135328A (zh) 2022-09-30
TW202135838A (zh) 2021-10-01
EP4122444A1 (en) 2023-01-25
TWI908184B (zh) 2025-12-11
JP2024133717A (ja) 2024-10-02
TW202442248A (zh) 2024-11-01
TWI796653B (zh) 2023-03-21
US20230165899A1 (en) 2023-06-01
WO2021185341A1 (zh) 2021-09-23
TWI827321B (zh) 2023-12-21
CN118236473A (zh) 2024-06-25
TW202438034A (zh) 2024-10-01
TW202135836A (zh) 2021-10-01
CN118557602A (zh) 2024-08-30
WO2021185377A1 (zh) 2021-09-23
CN118557604A (zh) 2024-08-30
TW202404618A (zh) 2024-02-01
CN115103683B (zh) 2024-04-09
CN118557603A (zh) 2024-08-30
WO2021185342A1 (zh) 2021-09-23
EP4122444A4 (en) 2024-04-17
TWI789724B (zh) 2023-01-11
TWI860566B (zh) 2024-11-01
TW202135839A (zh) 2021-10-01
TWI787761B (zh) 2022-12-21
TW202200781A (zh) 2022-01-01
CN115135328B (zh) 2024-01-02
CN115297872A (zh) 2022-11-04
TWI787763B (zh) 2022-12-21
TWI857807B (zh) 2024-10-01
US20230016499A1 (en) 2023-01-19
CN118319951A (zh) 2024-07-12
JP7736347B2 (ja) 2025-09-09
TWI853788B (zh) 2024-08-21
EP4122474A4 (en) 2024-05-01
CN117357559A (zh) 2024-01-09
CN119876009A (zh) 2025-04-25
TW202306576A (zh) 2023-02-16

Similar Documents

Publication Publication Date Title
US20230042445A1 (en) Use of mitochondria to promote wound repair and/or wound healing
US10022313B2 (en) Mesenchymal stem cell extract and its use
Hu et al. Combination of mesenchymal stem cell-conditioned medium and botulinum toxin type A for treating human hypertrophic scars
Guo et al. Comparison studies of the in vivo treatment of full‐thickness excisional wounds and burns by an artificial bilayer dermal equivalent and J‐1 acellular dermal matrix
CN108324926B (zh) 干细胞提取物和抗菌肽的组合物及其用途
WO2011036632A1 (en) Composition comprising a haematic component and its use for the treatment of degenerative joint disease
Zhao et al. Platelet-rich plasma (PRP) in the treatment of diabetic foot ulcers and its regulation of autophagy
US20200353008A1 (en) Compositions and methods for treating nerve injury
EP4228664A1 (en) Composition based on autologous platelet concentrates and a colostrum isolate mixture of biological factors for use in the treatment of conditions requiring tissue repair and regeneration
CN103405751B (zh) 一种具有细胞修复功能的组合物及其制备方法和应用
Palakkara et al. Healing potential of chitosan and decellularized intestinal matrix with mesenchymal stem cells and growth factor in burn wound in rat
TW201432048A (zh) 生長因子製劑及其生產方法
CN113143970A (zh) 促进糖尿病对象组织修复的方法及组合物
CN111358749B (zh) 一种促进皮肤伤口愈合的组合物及其制备方法
CN121588201B (zh) 用于宫颈肥大及毛鳞片修复的子宫内膜干细胞制剂及应用
KR101673318B1 (ko) 은나노 물질로 처리된 중간엽 줄기세포 또는 그 배양액을 유효성분으로 포함하는 상처 치료용 세포치료제 조성물
Tahir et al. Effect of Hylocereus polyrhizus Extract to VEGF and TGF-β1 Level in Acute Wound Healing of Wistar Rats
RU2646792C1 (ru) Средство для лошадей, обладающее регенеративной активностью
WO2024110937A1 (en) Compositions based on a mixture of bioactive molecules and exosomes for use in the treatment of conditions requiring tissue repair and regeneration
CN121629008A (zh) 一种基于VPA-Exo载药外泌体的促进皮肤创伤愈合体外评价模型及其构建方法和应用
CN121370715A (zh) 一种用于延缓细胞衰老、维持组织稳态的组合物及其制备方法和应用
CN113797316A (zh) 用于修复组织损伤的组合物及其制备方法和应用

Legal Events

Date Code Title Description
AS Assignment

Owner name: TAIWAN MITOCHONDRION APPLIED TECHNOLOGY CO., LTD., TAIWAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHENG, HAN-CHUNG;HSU, CHIH-KAI;TSENG, HUI-CHING;SIGNING DATES FROM 20220803 TO 20220805;REEL/FRAME:061442/0965

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION COUNTED, NOT YET MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION COUNTED, NOT YET MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION COUNTED, NOT YET MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED